Combining immune checkpoint inhibitors may help counter resistance pathways and increase the sensitivity to PD-1/PD-L1 treatment, offering the potential for improved anti-tumour responses and patient outcomes [19, 20]. This evidence concerns the gene PDCD1 and neoplasm.